Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04299048 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT04299048 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 11 participants.
The verdict
NCT04299048, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
Study to assess the safety and tolerability of repeated doses of an investigational new drug in patients with cancer and cachexia.
Interventions
- DRUG PF-06946860
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2020-11-17 |
| Est. Completion | 2022-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04299048
The ClinicalTrials.gov registry entry for NCT04299048 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-06946860 is the first listed.
NCT04299048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04299048 about?
NCT04299048 is a clinical study titled "Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.". Study to assess the safety and tolerability of repeated doses of an investigational new drug in patients with cancer and cachexia.
What is the current status of trial NCT04299048?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2020-11-17. Estimated completion is 2022-03-30.
What interventions are being tested in trial NCT04299048?
The interventions under investigation include: PF-06946860 (DRUG).
Who is sponsoring clinical trial NCT04299048?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.